Introduction
Injury to the central nervous system (CNS) often results in permanent deficits because axons fail to undergo regeneration, which is attributed to both extrinsic and intrinsic factors. Over the last three decades, there has been extensive focus on the characterization of extrinsic factors comprising the CNS environment, which has led to the identification of a growing list of axon growth impediments, such as myelin-based inhibitors and components in the glial scar [1] [2] [3] . Downstream signaling events that convey axon growth inhibition have also been investigated [1] [2] [3] [4] [5] in the hope of formulating axon regeneration strategies by alleviating the inhibitory influences ( Figure 1a) . However, although some issues still remain controversial [6] [7] [8] , recent studies suggest that counteracting the inhospitable milieu alone is insufficient to trigger long-distance axon regeneration [5, [9] [10] [11] [12] .
Another obstacle to axon regeneration is the age-dependent decline in intrinsic axon growth capacity. Recent attempts to augment the growth potential of mature neurons by regulating transcriptional [13] [14] [15] [16] or translational machineries [17, 18] have produced encouraging results. For successful axon regeneration, gene expression ( Figure 1b ) must harmonize with cytoskeletal dynamics (Figure 1c ) to appropriately redistribute signaling molecules and efficiently reassemble structural components. The mechanisms that control remodeling of the cytoskeletal components and the formation of an advancing growth cone after nerve injury will be of particular importance because these processes will directly impact the response to inhibitory molecules, the speed and extent of axon regeneration, and target innervation. Interventions aimed at promoting axon regeneration will eventually converge on cytoskeletal remodeling, but in this review we discuss the potential of and progress in enhancing axon regeneration by directly targeting cytoskeletal components in the growth cone.
Growth cone microtubules are potential targets for promoting axon regeneration Axon growth is driven by the forward movement of a growth cone, a specialized sensory motile structure located at the tip of a growing neurite. A growth cone is composed of a central domain rich in microtubules and a peripheral domain enriched in actin filaments. In accordance with the peripheral localization, the actin cytoskeleton plays a major part in pathfinding decisions in response to extrinsic cues. Microtubules, by contrast, are the building blocks of an axon, and thus axon extension occurs through microtubule assembly. Beyond their role as structural scaffolds, continuous remodeling of microtubules is vital for axon growth and guidance [19] [20] [21] [22] . Their inherent dynamicity enables microtubules to constantly explore the intracellular space, actively interact with signaling molecules and rapidly undergo reorganization in response to changes. Moreover, growth cone microtubules distribute
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Glossary
Microtubule plus end: microtubules are polymers of a-and b-tubulin dimers with a head-to-tail arrangement. The plus end, where b-tubulin is exposed, is the fast-growing end in vitro and the only end that grows in cells. Microtubule plus ends undergo cycles of rapid growth and shrinkage through the addition or removal of tubulin, a property known as dynamic instability. Microtubule-targeting agents: microtubule-targeting agents comprise a large number of chemically diverse substances that bind to distinct sites of microtubules (or soluble tubulin) and interfere with the normal functions of microtubules. Microtubule-targeting agents are often classified into two main groups, microtubule stabilizers (e.g. taxanes, such as taxol) and destabilizers (e.g. vinca alkaloids, such as vinblastine), according to their effects on microtubule polymer mass at high concentrations. However, at low concentrations, both classes of compounds suppress microtubule dynamics without changing the polymer mass. They are widely used as chemotherapeutic agents for the treatment of a wide variety of human cancers. Corresponding author: Zhou, F.-Q. (fzhou4@jhmi.edu)
